{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019067","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.791894+00:00","generated_at":"2026-06-08T03:17:50.402363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS Q3 net loss $2.4M, cash $16.9M; starts Phase 1a PMN310 Alzheimer's trial","bullets":["Net loss $2.4M in Q3 2023 vs $6.0M in Q3 2022; R&D expenses dropped to $1.1M from $4.6M.","Cash $16.9M at Sep 30, 2023, up from $5.9M at Dec 31, 2022, after $20.4M gross PIPE proceeds.","Phase 1a trial of PMN310 for Alzheimer's: first subjects dosing expected Nov 2023; early cohort results in H1 2024.","Raised $20.4M via private placement of ~10M shares and ~955K pre-funded warrants in August 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019067","json":"https://secwatch.observer/filing/0001558370-23-019067.json","markdown":"https://secwatch.observer/filing/0001558370-23-019067.md","text":"https://secwatch.observer/filing/0001558370-23-019067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019067/0001558370-23-019067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019067/pmn-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:17:50.402363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6c2fcdb9155a151347f60b93b447723459c85c6","claim":"ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $2.4 million for the quarter ended September 30, 2023.","evidence_excerpt":"ProMIS Neurosciences Inc. (the \"Company\") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019067/0001558370-23-019067-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $2.4 million for the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}